- Home
- ATXS vs RGC Comparison
ATXS vs RGC Comparison
Compare ATXS & RGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATXS
- RGC
- Stock Information
- Founded
- ATXS 2008
- RGC 2014
- Country
- ATXS United States
- RGC Hong Kong
- Employees
- ATXS N/A
- RGC N/A
- Industry
- ATXS Biotechnology: Pharmaceutical Preparations
- RGC Medicinal Chemicals and Botanical Products
- Sector
- ATXS Health Care
- RGC Health Care
- Exchange
- ATXS Nasdaq
- RGC Nasdaq
- Market Cap
- ATXS 401.2M
- RGC 377.5M
- IPO Year
- ATXS 2015
- RGC 2021
- Fundamental
- Price
- ATXS $4.76
- RGC $877.00
- Analyst Decision
- ATXS Strong Buy
- RGC
- Analyst Count
- ATXS 7
- RGC 0
- Target Price
- ATXS $32.43
- RGC N/A
- AVG Volume (30 Days)
- ATXS 625.9K
- RGC 94.8K
- Earning Date
- ATXS 05-13-2025
- RGC 06-20-2025
- Dividend Yield
- ATXS N/A
- RGC N/A
- EPS Growth
- ATXS N/A
- RGC N/A
- EPS
- ATXS N/A
- RGC N/A
- Revenue
- ATXS N/A
- RGC N/A
- Revenue This Year
- ATXS N/A
- RGC N/A
- Revenue Next Year
- ATXS N/A
- RGC N/A
- P/E Ratio
- ATXS N/A
- RGC N/A
- Revenue Growth
- ATXS N/A
- RGC N/A
- 52 Week Low
- ATXS $3.56
- RGC $3.03
- 52 Week High
- ATXS $12.92
- RGC $950.00
- Technical
- Relative Strength Index (RSI)
- ATXS 54.89
- RGC 80.93
- Support Level
- ATXS $3.83
- RGC $476.79
- Resistance Level
- ATXS $4.98
- RGC $560.00
- Average True Range (ATR)
- ATXS 0.45
- RGC 127.64
- MACD
- ATXS 0.11
- RGC 39.03
- Stochastic Oscillator
- ATXS 82.93
- RGC 89.80
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
About RGC Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.